Quality of Life in Patients with Atopic Dermatitis: Disease Burden, Measurement, and Treatment Benefit

American Journal of Clinical Dermatology

Volumn 17, Issue 2, 2016, Pages 163-169

  Blome, Christine ^a   Radtke, Marc A ^a   Eissing, Leah ^a   Augustin, Matthias ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ATOPIC DERMATITIS; CLINICAL PRACTICE; DERMATOLOGY LIFE QUALITY INDEX; DISEASE SEVERITY; HUMAN; PATIENT EDUCATION; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; ADULT; CHILD; CLIMATOTHERAPY; COST OF ILLNESS; DERMATITIS, ATOPIC; FEMALE; INFANT; MALE; OBSERVATIONAL STUDY; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

GLUCOCORTICOID; IMMUNOSUPPRESSIVE AGENT; PROBIOTIC AGENT;

ADULT; CHILD; CLIMATOTHERAPY; COST OF ILLNESS; DERMATITIS, ATOPIC; FEMALE; GLUCOCORTICOIDS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFANT; MALE; OBSERVATIONAL STUDIES AS TOPIC; PROBIOTICS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEVERITY OF ILLNESS INDEX; SURVEYS AND QUESTIONNAIRES; TREATMENT OUTCOME;

EID: 84961730114     PISSN: 11750561     EISSN: 11791888     Source Type: Journal    
DOI: 10.1007/s40257-015-0171-3     Document Type: Review

References (47)

1. Bullinger M. Assessing health related quality of life in medicine: an overview over concepts, methods and applications in international research. Restor Neurol Neurosci. 2002;20:93–101.
2. Schafer I, Hacker J, Rustenbach SJ, et al. Concordance of the Psoriasis Area and Severity Index (PASI) and patient-reported outcomes in psoriasis treatment. Eur J Dermatol. 2010;20:62–7. doi:10.1684/ejd.2010.0815.
3. Maksimovic N, Jankovic S, Marinkovic J, et al. Health-related quality of life in patients with atopic dermatitis. J Dermatol. 2012;39:42–7. doi:10.1111/j.1346-8138.2011.01295.x.
4. Langenbruch A, Radtke M, Franzke N, et al. Quality of health care of atopic eczema in Germany: results of the national health care study AtopicHealth. J Eur Acad Dermatol Venereol. 2014;28:719–26. doi:10.1111/jdv.12154.
5. van Valburg, Rosalinda W C, Willemsen MG, et al. Quality of life measurement and its relationship to disease severity in children with atopic dermatitis in general practice. Acta Derm Venereol. 2011;91:147–51. doi:10.2340/00015555-1026.
6. Blome C, Augustin M, Siepmann D, et al. Measuring patient-relevant benefits in pruritus treatment: development and validation of a specific outcomes tool. Br J Dermatol. 2009;161:1143–8. doi:10.1111/j.1365-2133.2009.09328.x.
7. Basra MKA, Fenech R, Gatt RM, et al. The Dermatology Life Quality Index 1994-2007: a comprehensive review of validation data and clinical results. Br J Dermatol. 2008;159:997–1035. doi:10.1111/j.1365-2133.2008.08832.x.
8. Charman CR, Venn AJ, Williams HC. The patient-oriented eczema measure: development and initial validation of a new tool for measuring atopic eczema severity from the patients’ perspective. Arch Dermatol. 2004;140:1513–9. doi:10.1001/archderm.140.12.1513.
9. Nutten S. Atopic dermatitis: global epidemiology and risk factors. Ann Nutr Metab. 2015;66(Suppl 1):8–16. doi:10.1159/000370220.
10. Kiebert G, Sorensen SV, Revicki D, et al. Atopic dermatitis is associated with a decrement in health-related quality of life. Int J Dermatol. 2002;41:151–8.
11. Lundberg L, Johannesson M, Silverdahl M, et al. Health-related quality of life in patients with psoriasis and atopic dermatitis measured with SF-36, DLQI and a subjective measure of disease activity. Acta Derm Venereol. 2000;80:430–4.
12. Beikert FC, Langenbruch AK, Radtke MA, et al. Willingness to pay and quality of life in patients with atopic dermatitis. Arch Dermatol Res. 2014;306:279–86. doi:10.1007/s00403-013-1402-1.
13. Misery L, Finlay AY, Martin N, et al. Atopic dermatitis: impact on the quality of life of patients and their partners. Dermatology. 2007;215:123–9. doi:10.1159/000104263.
14. Ricci G, Bendandi B, Bellini F, et al. Atopic dermatitis: quality of life of young Italian children and their families and correlation with severity score. Pediatr Allergy Immunol. 2007;18:245–9. doi:10.1111/j.1399-3038.2006.00502.x.
15. Chamlin SL, Frieden IJ, Williams ML, et al. Effects of atopic dermatitis on young American children and their families. Pediatrics. 2004;114:607–11. doi:10.1542/peds.2004-0374.
16. Yaghmaie P, Koudelka CW, Simpson EL. Mental health comorbidity in patients with atopic dermatitis. J Allergy Clin Immunol. 2013;131:428–33. doi:10.1016/j.jaci.2012.10.041.
17. Slattery MJ, Essex MJ, Paletz EM, et al. Depression, anxiety, and dermatologic quality of life in adolescents with atopic dermatitis. J Allergy Clin Immunol. 2011;128:668–71. doi:10.1016/j.jaci.2011.05.003.
18. Beattie PE, Lewis-Jones MS. A comparative study of impairment of quality of life in children with skin disease and children with other chronic childhood diseases. Br J Dermatol. 2006;155:145–51. doi:10.1111/j.1365-2133.2006.07185.x.
19. Carroll CL, Balkrishnan R, Feldman SR, et al. The burden of atopic dermatitis: impact on the patient, family, and society. Pediatr Dermatol. 2005;22:192–9. doi:10.1111/j.1525-1470.2005.22303.x.
20. Lewis-Jones S. Quality of life and childhood atopic dermatitis: the misery of living with childhood eczema. Int J Clin Pract. 2006;60:984–92. doi:10.1111/j.1742-1241.2006.01047.x.
21. Mozaffari H, Pourpak Z, Pourseyed S, et al. Quality of life in atopic dermatitis patients. J Microbiol Immunol Infect. 2007;40:260–4.
22. Ware JE Jr, Sherbourne CD. The MOS 36-item Short-Form Health Survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992;30:473–83.
23. Lewis-Jones MS, Finlay AY. The Children’s Dermatology Life Quality Index (CDLQI): initial validation and practical use. Br J Dermatol. 1995;132:942–9.
24. Holme SA, Man I, Sharpe JL, et al. The Children’s Dermatology Life Quality Index: validation of the cartoon version. Br J Dermatol. 2003;148:285–90.
25. Basra MKA, Sue-Ho R, Finlay AY. The Family Dermatology Life Quality Index: measuring the secondary impact of skin disease. Br J Dermatol. 2007;156:528–38. doi:10.1111/j.1365-2133.2006.07617.x.
26. Whalley D, McKenna SP, Dewar AL, et al. A new instrument for assessing quality of life in atopic dermatitis: international development of the Quality of Life Index for Atopic Dermatitis (QoLIAD). Br J Dermatol. 2004;150:274–83.
27. Basra MKA, Gada V, Ungaro S, et al. Infants’ Dermatitis Quality of Life Index: a decade of experience of validation and clinical application. Br J Dermatol. 2013;169:760–8. doi:10.1111/bjd.12563.
28. Schmitt J, Spuls PI, Thomas KS, et al. The Harmonising Outcome Measures for Eczema (HOME) statement to assess clinical signs of atopic eczema in trials. J Allergy Clin Immunol. 2014;134:800–7. doi:10.1016/j.jaci.2014.07.043.
29. Home IV Meeting. Harmonising outcome measures for eczema. Available from: http://www.nottingham.ac.uk/homeforeczema/documents/home-iv-meeting-minutes.pdf. Accessed 12 Jan 2016.
30. Rehal B, Armstrong AW. Health outcome measures in atopic dermatitis: a systematic review of trends in disease severity and quality-of-life instruments 1985-2010. PLoS One. 2011;6:e17520. doi:10.1371/journal.pone.0017520.
31. McKenna SP, Whalley D, de Prost Y, et al. Treatment of paediatric atopic dermatitis with pimecrolimus (Elidel, SDZ ASM 981): impact on quality of life and health-related quality of life. J Eur Acad Dermatol Venereol. 2006;20:248–54. doi:10.1111/j.1468-3083.2006.01383.x.
32. Staab D, Kaufmann R, Brautigam M, et al. Treatment of infants with atopic eczema with pimecrolimus cream 1 % improves parents’ quality of life: a multicenter, randomized trial. Pediatr Allergy Immunol. 2005;16:527–33. doi:10.1111/j.1399-3038.2005.00306.x.
33. Janmohamed SR, Oranje AP, Devillers AC, et al. The proactive wet-wrap method with diluted corticosteroids versus emollients in children with atopic dermatitis: a prospective, randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol. 2014;70:1076–82. doi:10.1016/j.jaad.2014.01.898.
34. Meggitt SJ, Gray JC, Reynolds NJ. Azathioprine dosed by thiopurine methyltransferase activity for moderate-to-severe atopic eczema: a double-blind, randomised controlled trial. Lancet. 2006;367:839–46. doi:10.1016/S0140-6736(06)68340-2.
35. Hon KLE, Leung TF, Ng PC, et al. Efficacy and tolerability of a Chinese herbal medicine concoction for treatment of atopic dermatitis: a randomized, double-blind, placebo-controlled study. Br J Dermatol. 2007;157:357–63. doi:10.1111/j.1365-2133.2007.07941.x.
36. Drago L, Iemoli E, Rodighiero V, et al. Effects of Lactobacillus salivarius LS01 (DSM 22775) treatment on adult atopic dermatitis: a randomized placebo-controlled study. Int J Immunopathol Pharmacol. 2011;24:1037–48.
37. Drago L, Toscano M, de Vecchi E, et al. Changing of fecal flora and clinical effect of L. salivarius LS01 in adults with atopic dermatitis. J Clin Gastroenterol. 2012;46(Suppl):S56–63. doi:10.1097/MCG.0b013e318265ef38.
38. Matsumoto M, Ebata T, Hirooka J, et al. Antipruritic effects of the probiotic strain LKM512 in adults with atopic dermatitis. Ann Allergy Asthma Immunol. 2014;113:209–216.e7; doi:10.1016/j.anai.2014.05.002.
39. Gerasimov SV, Vasjuta VV, Myhovych OO, et al. Probiotic supplement reduces atopic dermatitis in preschool children: a randomized, double-blind, placebo-controlled, clinical trial. Am J Clin Dermatol. 2010;11:351–61. doi:10.2165/11531420-000000000-00000.
40. Byremo G, Rod G, Carlsen KH. Effect of climatic change in children with atopic eczema. Allergy. 2006;61:1403–10. doi:10.1111/j.1398-9995.2006.01209.x.
41. Grillo M, Gassner L, Marshman G, et al. Pediatric atopic eczema: the impact of an educational intervention. Pediatr Dermatol. 2006;23:428–36. doi:10.1111/j.1525-1470.2006.00277.x.
42. Weber MB, de Fontes Neto P, da Luz Tarso, Prati C, et al. Improvement of pruritus and quality of life of children with atopic dermatitis and their families after joining support groups. J Eur Acad Dermatol Venereol. 2008;22:992–7. doi:10.1111/j.1468-3083.2008.02697.x.
43. Staab D, Diepgen TL, Fartasch M, et al. Age related, structured educational programmes for the management of atopic dermatitis in children and adolescents: multicentre, randomised controlled trial. BMJ. 2006;332:933–8. doi:10.1136/bmj.332.7547.933.
44. Ersser SJ, Latter S, Sibley A, et al. Psychological and educational interventions for atopic eczema in children. Cochrane Database Syst Rev. 2007;(3):CD004054. doi:10.1002/14651858.CD004054.pub2.
45. Blome C, Augustin M. Measuring change in quality of life: bias in prospective and retrospective evaluation. Value Health. 2015;18:110–5. doi:10.1016/j.jval.2014.10.007.
46. Steinke S, Langenbruch A, Stander S, et al. Therapeutic benefits in atopic dermatitis care from the patients’ perspective: results of the German national health care study ‘Atopic Health’. Dermatology. 2014;228:350–9. doi:10.1159/000358587.
47. Augustin M, Radtke MA, Zschocke I, et al. The patient benefit index: a novel approach in patient-defined outcomes measurement for skin diseases. Arch Dermatol Res. 2009;301:561–71. doi:10.1007/s00403-009-0928-8.